» Articles » PMID: 24748881

Cutting-balloon Angioplasty Before Drug-eluting Stent Implantation for the Treatment of Severely Calcified Coronary Lesions

Overview
Specialty Geriatrics
Date 2014 Apr 22
PMID 24748881
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Severely calcified coronary lesions respond poorly to balloon angioplasty, resulting in incomplete and asymmetrical stent expansion. Therefore, adequate plaque modification prior to drug-eluting stent (DES) implantation is the key for calcified lesion treatment. This study was to evaluate the safety and efficacy of cutting balloon angioplasty for severely calcified coronary lesions.

Methods: Ninety-two consecutive patients with severely calcified lesions (defined as calcium arc ≥ 180° calcium length ratio ≥ 0.5) treated with balloon dilatation before DES implantation were randomly divided into two groups based on the balloon type: 45 patients in the conventional balloon angioplasty (BA) group and 47 patients in the cutting balloon angioplasty (CB) group. Seven cases in BA group did not satisfactorily achieve dilatation and were transferred into the CB group. Intravascular ultrasound (IVUS) was performed before balloon dilatation and after stent implantation to obtain qualitative and quantitative lesion characteristics and evaluate the stent, including minimum lumen cross-sectional area (CSA), calcified arc and length, minimum stent CSA, stent apposition, stent symmetry, stent expansion, vessel dissection, and branch vessel jail. In-hospital, 1-month, and 6-month major adverse cardiac events (MACE) were reported.

Results: There were no statistical differences in clinical characteristics between the two groups, including calcium arc (222.2° ± 22.2° vs. 235.0° ± 22.1°, P = 0.570), calcium length ratio (0.67 ± 0.06 vs. 0.77 ± 0.05, P = 0.130), and minimum lumen CSA before PCI (2.59 ± 0.08 mm(2) vs. 2.52 ± 0.08 mm(2), P = 0.550). After stent implantation, the final minimum stent CSA (6.26 ± 0.40 mm(2) vs. 5.03 ± 0.33 mm(2); P = 0.031) and acute lumen gain (3.74 ± 0.38 mm(2) vs. 2.44 ± 0.29 mm(2), P = 0.015) were significantly larger in the CB group than that of the BA group. There were not statistically differences in stent expansion, stent symmetry, incomplete stent apposition, vessel dissection and branch vessel jail between two groups. The 30-day and 6-month MACE rates were also not different.

Conclusions: Cutting balloon angioplasty before DES implantation in severely calcified lesions appears to be more efficacies including significantly larger final stent CSA and larger acute lumen gain, without increasing complications during operations and the MACE rate in 6-month.

Citing Articles

Enhanced Efficiency of Sequential Cutting Balloon Angioplasty in Calcified Coronary Artery Disease: The RODIN-CUT Technique.

Ungureanu C, Leibundgut G, Cocoi M, Gasparini G, Colletti G, Avran A Catheter Cardiovasc Interv. 2025; 105(4):805-812.

PMID: 39757754 PMC: 11874252. DOI: 10.1002/ccd.31387.


Assessment of Cutting-Balloon Angioplasty with Novel Bioabsorbable Polymer-Coated Everolimus-Eluting Stent in Treating Calcified Coronary Lesions Guided by Intravascular Ultrasound (CUPID Trial): study design and protocol.

Ahn J, Yu H, Park S, Suh J Trials. 2024; 25(1):727.

PMID: 39472953 PMC: 11520680. DOI: 10.1186/s13063-024-08484-0.


Procedural safety of rotational atherectomy and modified balloon angioplasty: insights from a German national registry.

Maier A, Gissler M, Jackel M, Oettinger V, Bacmeister L, Heidenreich A Clin Res Cardiol. 2024; .

PMID: 39259363 DOI: 10.1007/s00392-024-02538-8.


Modified balloons to prepare severely calcified coronary lesions before stent implantation: a systematic review and meta-analysis of randomized trials.

Scalamogna M, Kuna C, Voll F, Aytekin A, Lahu S, Kessler T Clin Res Cardiol. 2023; 113(7):995-1005.

PMID: 37930402 PMC: 11219378. DOI: 10.1007/s00392-023-02324-y.


Comparison of long-term outcome in patients with calcified stenosis treated with intravascular lithotripsy or with modified balloon angioplasty: a propensity score-adjusted study.

Leick J, Rheude T, Denne M, Cassese S, Kastrati A, Hauptmann F Front Cardiovasc Med. 2023; 10:1185422.

PMID: 37255702 PMC: 10225498. DOI: 10.3389/fcvm.2023.1185422.


References
1.
Fujii K, Carlier S, Mintz G, Yang Y, Moussa I, Weisz G . Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. 2005; 45(7):995-8. DOI: 10.1016/j.jacc.2004.12.066. View

2.
Kronmal R, McClelland R, Detrano R, Shea S, Lima J, Cushman M . Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007; 115(21):2722-30. DOI: 10.1161/CIRCULATIONAHA.106.674143. View

3.
Chiang M, Yi H, Tsao C, Chang W, Su C, Liu T . Rotablation in the treatment of high-risk patients with heavily calcified left-main coronary lesions. J Geriatr Cardiol. 2013; 10(3):217-25. PMC: 3796693. DOI: 10.3969/j.issn.1671-5411.2013.03.009. View

4.
Roy P, Steinberg D, Sushinsky S, Okabe T, Pinto Slottow T, Kaneshige K . The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J. 2008; 29(15):1851-7. DOI: 10.1093/eurheartj/ehn249. View

5.
Song H, Kang S, Ahn J, Kim W, Lee J, Park D . Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2012; 83(6):873-8. DOI: 10.1002/ccd.24560. View